衞生防護中心
Centre for Health Protection

Antimicrobial Resistance (AMR) Surveillance on Culture Specimens in Public Hospitals and Clinics - Hospital Authority AMR Data (2024)

December 2025

衞生署
Department of Health

Contents Outline

- Results
  - Overview on patients with blood, urine, stool, CSF and lower respiratory cultures
  - Overview on WHO priority organisms isolates from blood, urine, stool, CSF and lower respiratory cultures
  - Antimicrobial susceptibility test result
- Summary

衞生防護中心
Centre for Health Protection

Results - CSF Culture

Overview on patients with CSF culture

衞生署
Department of Health

Age distribution of patients with CSF culture



- No. of patients with CSF culture remained stable in 2023 and 2024.

Percentage of patients with positive CSF culture



- % patients with positive CSF culture remained stable from 2020 to 2024 at less than 2%.

Results - CSF Culture

Overview on WHO priority organisms isolated from CSF

Distribution of organisms by year



- Among the WHO priority organisms cultured from CSF between 2016 to 2024, no single pathogen remained consistently dominant.

Distribution of organisms by location of onset



- H. influenzae, S. pneumoniae, N. meningitidis were predominantly community-onset from 2016 to 2024.
- More than half of S. aureus, P. aeruginosa and Acinetobacter spp. isolated were hospital-onset.

衞生署
Department of Health

CSF Culture- AST results

No AST results available as < 10 isolates tested for each organism (WHO GLASS manual)

Summary



Note: Only drug-bug combinations with more than 10 isolates and at least 70% of isolates tested for susceptibility in 2024 are shown.

- Enterobacterales (E. coli, K. pneumoniae) remain sensitive to carbapenems (ertapenem/meropenem; 0-10% NS), Acinetobacter spp. exhibit high carbapenem resistance (>50% NS to imipenem/meropenem in hospital blood/respiratory isolates).

Summary



Note: Only drug-bug combinations with more than 10 isolates and at least 70% of isolates tested for susceptibility in 2024 are shown.

- Urinary E. coli: High Levofloxacin NS (41-50% Community & Hospital) and Co-trimoxazole NS (31-40% Comm, 41-50% Hosp) contrast with preserved Nitrofurantoin/Amikacin susceptibility (0-10% NS).